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Host immunity provides wide spectrum protection that serves to eradicate pathogens
and cancer cells, while maintaining self-tolerance and immunological homeostasis.
Ligation of the T  cell receptor (TCR) by antigen activates signaling pathways that
coordinately induce aerobic glycolysis, mitochondrial activity, anabolic metabolism, and 
T effector cell differentiation. Activation of PI3K, Akt, and mTOR triggers the switch to
anabolic metabolism by inducing transcription factors such as Myc and HIF1, and the
glucose transporter Glut1, which is pivotal for the increase of glucose uptake after T cell 
activation. Activation of MAPK signaling is required for glucose and glutamine utiliza-
tion, whereas activation of AMPK is critical for energy balance and metabolic fitness of 
T effector and memory cells. Coinhibitory receptors target TCR-proximal signaling and
generation of second messengers. Imbalanced activation of such signaling pathways
leads to diminished rates of aerobic glycolysis and impaired mitochondrial function
resulting in defective anabolic metabolism and altered T cell differentiation. The coin-
hibitory receptors mediate distinct and synergistic effects on the activation of signaling
pathways thereby modifying metabolic programs of activated T cells and resulting in
altered immune functions. Understanding and therapeutic targeting of metabolic pro-
grams impacted by coinhibitory receptors might have significant clinical implications for 
the treatment of chronic infections, cancer, and autoimmune diseases.
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T CeLL COiNHiBiTORY ReCePTORS
When the T  cell receptor (TCR) is engaged, tyrosine phosphorylation of the TCR-associated 
CD3 chains recruits kinases and scaffold proteins leading to the formation of a supramolecular 
complex that promotes activation of signaling cascades, generation of second messengers, and 
initiation of transcriptional events, which lead to T cell differentiation programs (1). These signal-
ing pathways synergistically promote glycolysis and anabolic metabolism to support T cell clonal 
expansion and effector cell generation (2–4). It is now well understood that metabolic mediators 
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function as intermediates between these signaling events and 
the  functional outcome of T  cell activation. Costimulatory 
receptors, engaged simultaneously with the TCR, have a major 
impact on signaling events and a decisive role in the differ-
entiation program of T  cells. Thus, their role in altering the 
immunometabolic programming mediated by TCR-mediated 
activation is unequivocal (5–7).
Our understanding about the functional role of costimulation 
has evolved from the two-signal model proposed by Lafferty 
and Cunningham to explain the activation of naïve T  cells 
(8, 9). Although T cell costimulatory pathways were envisioned as 
stimulators of T cell responses by that model, it is now clear that 
both stimulatory (costimulatory) and inhibitory (coinhibitory) 
second signals exist and mediate their impact not only in naïve 
(TN) but also in effector (TEFF), memory (TM), and regulatory 
(TREG) T cells (10–12). These receptors are key regulators of T cell 
activation, tolerance, and exhaustion, and therapeutic modula-
tion of costimulatory and coinhibitory pathways provides effec-
tive new treatment strategies in cancer, autoimmunity, infectious 
diseases, and allogeneic transplantation (13–15).
The first costimulatory receptor CD28 and the first coinhibi-
tory receptor CTLA-4 and their shared ligands CD80 (B7-1) 
and CD86 (B7-2) constitute the best-characterized pathway, 
which serves as a paradigm for other costimulatory and coin-
hibitory pathways. The massive lymphoproliferation and organ 
infiltration by activated T cells in the CTLA-4-deficient mice 
(16, 17) was the first indication that coinhibitory receptors have 
a mandatory role in the regulation of T cell tolerance. Today, 
many additional costimulatory and coinhibitory receptors have 
been identified, and their role in the induction and mainte-
nance of T cell tolerance has been established (Figure 1). These 
pathways fall into two major families: the Ig superfamily, which 
includes the B7–CD28, TIM, CD226–TIGIT–CD96 families as 
well as LAG-3, and the TNF–TNF receptor superfamily (18–
20). Coinhibitory receptors provide a balance on the activation 
and expansion of antigen-specific T cells upon encounter with 
antigen but also regulate T  cell tolerance by restraining the 
initial activation of naïve self-reactive T cells and/or responses 
of harmful self-reactive T  cells. Coinhibitory pathways also 
regulate the generation and function of thymic-derived TREG 
and TREG generated at peripheral sites (21, 22). Ligands for vari-
ous coinhibitory receptors are expressed on antigen-presenting 
cells (APCs) but also in non-hematopoietic cells (18–20). The 
expression of coinhibitory ligands on non-hematopoietic cells 
has a key role for the maintenance of tissue tolerance by sup-
pressing the expansion and function of self-reactive T  cells. 
Importantly, tumors and infectious agents that cause chronic 
infections exploit these natural tolerance mechanisms to evade 
surveillance and attack by the immune system (13, 23).
Coinhibitory receptors have a major impact on the differentia-
tion fate of T cells as well as on their ability to proliferate. These 
functional endpoints are regulated by T  cell metabolic repro-
gramming (24, 25). Therefore, altering metabolic reprogramming 
might be a key mechanism by which coinhibitory receptors 
modify T  cell differentiation and function. Because various 
coinhibitory receptors mediate distinct effects on the activation of 
signaling pathways downstream of the TCR, the role of coinhibi-
tory receptors on altering the metabolic programs of T cells is also 
anticipated to be different. Identification and targeting the specific 
immunometabolic pathways relayed by coinhibitory receptors 
might have significant clinical implications. For example, selec-
tive receptor targeting might be employed in order to achieve 
specific desired modifications in the metabolic programs and 
functional fates of T cells. In this review, first, we will discuss the 
current understanding of the mechanisms underlying metabolic 
programs induced during T cell differentiation and how these are 
affected by cytotoxic lymphocyte antigen-4 (CTLA-4) and pro-
grammed death-1 (PD-1), the two most clinically relevant coin-
hibitory receptors thus far, for which therapeutic targeting has 
achieved major success in cancer treatment. Next, we will review 
briefly other inhibitory pathways, and we will discuss lympho-
cyte activation gene-3 (LAG-3), T cell-immunoglobulin–mucin 
domain 3 (TIM-3), and T cell immunoglobulin and ITIM domain 
(TIGIT), which are additional promising therapeutic targets. 
Finally, we will briefly discuss the CD160/B and T  lymphocyte 
attenuator (BTLA)/LIGHT/herpesvirus entry mediator (HVEM) 
pathway, which has the rare property to engage members of the 
Ig superfamily and the TNF receptor superfamily and to deliver 
both coinhibitory and costimulatory signals (Please see glossary 
in Supplementary Material).
iMMUNOMeTABOLiSM AND T CeLL 
DiFFeReNTiATiON
Similar to the metabolism of other non-proliferating cells, naïve 
T cells depend on catabolic metabolism to meet their energetic 
needs, relying predominantly on oxidative phosphorylation 
(OXPHOS) to generate ATP (26). Extrinsic IL-7 survival signal 
maintains naïve T cell quiescence, a mechanism that relies on 
tuberous sclerosis (TSC) function to keep mTOR activation 
in check (27–29). Upon antigen encounter, T  cells switch to 
anabolic metabolism to meet the increased metabolic demands 
of biomass accumulation, proliferation, and biosynthesis of 
mediators of effector functions (Figures 2 and 3A). Signaling 
via the TCR is sufficient to upregulate expression of the glucose 
transporter Glut1 via Myc (30). However, the metabolic repro-
gramming accompanying the differentiation into TEFF requires 
costimulation. Signaling via CD28 costimulation activates the 
PI3K/Akt/mTOR pathway, which is crucial to activate aerobic 
glycolysis required for T cell differentiation and function (6, 31, 
32). mTOR has a key role in regulating metabolism coupling 
nutrient availability to cell growth and division (33, 34).
After pathogen clearance, antigen-specific T  cells undergo 
contraction, and most TEFF cells undergo cell death. A small 
subset survives and goes on to become TM cells. TM cells exhibit 
a distinctive increase in mitochondrial mass and higher spare 
respiratory capacity (SRC) (35). This is a consequence of fusion 
in the mitochondria of TM cells, which configures associations of 
the electron transport chain and favors OXPHOS (36). In con-
trast to TEFF, which rely predominantly on glycolytic metabolism, 
TM rely on mitochondrial fatty acid oxidation (FAO) of de novo 
FigURe 1 | Coinhibitory pathways. T cell activation is initiated by recognition of antigens presented by antigen-presenting cells (APCs) to the T cell receptor 
(TCR)–CD3 complex in the presence of CD28 costimulation. CD28 is the prototype costimulatory receptor and interacts with CD80 and CD86. Many coinhibitory 
pathways are upregulated upon T cell activation and can attenuate TCR and costimulatory signals. Coinhibitory pathways in the B7–CD28 family control responses 
of naive, effector, regulatory, memory, and exhausted T cells. Ligands for coinhibitory receptors are expressed on APCs, non-hematopoietic cells, tumors, and some 
of them also on T cells. The receptors for B7-H3 and B7-H4 and their effects remain unclear. Binding ligands for VISTA have not been identified. Continuous lines 
indicate interactions mediating stimulatory effects, and dotted lines indicate interactions mediating inhibitory effects.
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synthesized FA, rather than uptake of lipids (37). During TCR 
engagement with APCs, T  cells can divide asymmetrically. It 
has been determined that the APC-proximal daughter gener-
ated during cell division is more likely to become a TEFF while 
the APC-distal daughter cell is more likely to differentiate into 
a TM (38). In addition to its role in promoting glycolysis, asym-
metric Myc sorting between the daughter cells plays a role in 
the distribution of amino acid content and transporters as well 
as mTORC1. This results in altered metabolism and thus altered 
proliferation and differentiation that may give rise to effector 
versus memory fates of the daughter cells (39). This is likely not 
the only mechanism to generate TM cells, as other studies have 
shown that TEFF cells are the ones that can give rise to TM (40, 41). 
Enforcing the metabolic switch to FAO by enhancing AMPK or 
by inhibiting mTOR results in increased numbers of TM cells 
(42, 43). In mammalian cells, mTOR forms functionally distinct 
complexes—mTORC1 and mTORC2. Raptor and Rictor are the 
core adaptor subunits of mTORC1 and mTORC2, respectively. 
Interestingly, T  cells deficient in Rictor show enhanced CD8 
memory formation with enhanced recall responses without 
dampening effector functions (44).
Since the activation of T cells requires accompanying meta-
bolic reprogramming for differentiation, it is no surprise that 
metabolism drives the differentiation of CD4 T helper (Th) subsets 
as well. Th1, Th2, Th17, and TREG cells are the best metabolically 
defined thus far. Initial evidence showing their metabolic distinc-
tion came when suppression of mTOR by rapamycin prevented 
TEFF proliferation and instead promoted TREG generation, even in 
Th17 polarizing conditions (45). Genetic deletion of mTOR in 
T cells confirmed the results of pharmacological inhibition and 
caused production of only TREG, illustrating the obligatory role of 
mTOR for TEFF production (46). Furthermore, TEFF show a strong 
preference for glycolytic rather than mitochondrial metabolism, 
whereas TREG rely more on the oxidation of lipids (47).
FigURe 2 | T cell differentiation is accompanied by metabolic changes, which are affected by costimulatory and coinhibitory receptors. Naïve T cells 
function in antigenic surveillance and do not proliferate. This requires minimal energetic and biosynthetic activity, which is represented by a metabolically quiescent 
state, and is accompanied by minimal nutrient uptake. Their only energy-demanding processes are ion homeostasis, membrane integrity, and movement. The 
primary ATP sources are oxidative phosphorylation (OXPHOS) and fatty acid oxidation (FAO) to fuel the low energy demand. Upon antigen encounter T cells 
differentiate into effector cells. This process is accompanied by metabolic changes, which are required to fulfill their new (effector) functions and rapid proliferation. 
Uptake of nutrients is enhanced. Glucose is the main nutrient used for energy and for generation of biosynthetic precursors. These changes combined with 
increased glutaminolysis and a high degree of protein, lipid, and nucleic acid synthesis support cell growth and proliferation. These metabolic changes coincide with 
mitochondria fission. Memory T cells do not proliferate and thus have minimal biosynthesis and nutrient uptake. However, they have increased spare respiratory 
capacity, which supports their ability to rapidly proliferate upon re-encounter of antigen. This cellular fate includes another metabolic adaption, which supports 
metabolic switch to FAO via increased carnitine palmitoyltransferase 1A. These metabolic and energetic changes are supported by fusion of mitochondria.
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Th17 cells are particularly dependent on glycolysis. Although 
Myc is dominant over the hypoxia-inducible factor 1α (HIF1α) in 
regulating differentiation of naïve T cells into TEFF cells (30), HIF1α 
has a key role in the metabolic switch to aerobic glycolysis that 
influences the balance of Th17/TREG in favor of Th17 cells. Genetic 
deletion of HIF1α in mice or blocking glycolysis with 2-deoxy-
glucose showed reduced Th17 and enhanced TREG development 
(48). HIF1α in coordination with RORγt and p300 promotes the 
development of Th17  cells while concurrently weakening the 
development of TREG cells by promoting proteasomal degradation 
of FoxP3 (49). Furthermore, differentiation of Th1 and Th17 cells 
is selectively regulated by mTORC1 while Th2 differentiation is 
regulated by mTORC2 (50).
It should be noted that glycolytic enzymes themselves might 
also have an active role in regulating TEFF cell function. For 
example, it has been proposed that when glycolytic rates are low 
in Th1 CD4+ T cells, glyceraldehyde phosphate dehydrogenase 
(GAPDH) binds to and suppresses IFN-γ mRNA translation 
(51). In effector memory CD8+ T cells, glycolysis was observed 
to impact chromatin remodeling in the promoter region of the 
IFN-γ gene, thus facilitating gene transcription (52). In addition, 
naïve T cells express both isoforms of the glycolytic enzyme pyru-
vate kinase, PKM1 and PKM2, which catalyzes the conversion 
of phosphoenolpyruvate to pyruvate. After activation, the M2 
isoform rapidly accumulates and is the dominant form expressed 
in TEFF cells (53, 54). The M2 isoform is less efficient, but this 
skews glycolysis toward biosynthetic pathways and may give 
cells a growth advantage during rapid proliferation (55). Because 
coinhibitory receptors are induced after T cell activation, a pro-
cess that is dependent on glycolysis, there might be a correlation 
between the expression and function of glycolytic enzymes and 
coinhibitory receptors. These findings provide evidence for an 
intimate causative link among TCR-mediated signaling, T  cell 
metabolism, and T cell differentiation.
TCR-MeDiATeD SigNALiNg eveNTS 
DRive T CeLL MeTABOLiC 
RePROgRAMMiNg
Signaling pathways activated by engagement of the TCR and 
costimulatory receptors and CD28, the prototype costimulatory 
receptor, activates the PI3K/Akt/mTOR and MEK/Erk MAPK 
pathways, and their simultaneous activation is required to 
promote T cell growth, division, and cytokine production (56) 
(Figure 3A). Autocrine and paracrine cytokine signaling loops 
induce further PI3K and MAPK activation, together with JAK/
STAT signaling (57, 58). PI3K catalyzes the production of the 
second messenger phosphatidylinositol 3,4,5-trisphosphate 
[PI(3,4,5)P3], leading to the activation of several downstream 
kinases, including Akt, its most prominent effector. In naïve 
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FigURe 3 | Continued
FigURe 3 | Continued  
(A) Upon antigen encounter T cells differentiate into effector cells. Antigen binding to the T cell receptor (TCR) and coactivation by CD28 inhibit fatty acid oxidation 
(FAO) and activate PI3K-Akt. This activation triggers glycolytic enzymes HK and PFK2. Additionally, mTOR signaling is turned on, which enhances expression of 
glycolytic genes, glucose, and amino acid transporters via activation of transcription factors HIF1α and Myc. Activation of PLC-γ1 and generation of second 
messengers result in activation of Ras and MEK/Erk pathway, which is required for expression of nutrient transporters and nutrient utilization. Calcium release 
activates calcium-dependent mitochondrial dehydrogenases, which activate the TCA cycle. Effector T cells also switch from balanced PKM1 and PKM2 expression 
to increased and predominant expression of PKM2, which promotes generation of biosynthetic precursors. These events promote glucose and glutamine uptake, 
increased glycolysis and glutaminolysis combined with a high degree of protein, lipid, and nucleic acid synthesis to support cell growth and proliferation. CD28 
costimulation is required for activation of the signaling pathways that support these metabolic changes. (B) Cytotoxic T lymphocyte antigen-4 (CTLA-4) and 
programmed death-1 (PD-1) coinhibitory receptors are expressed in activated T cells. Via the recruitment of phosphatases, both these coinhibitory receptors 
attenuate the signaling events mediated by ligation of the TCR by antigen and have a mandatory role in the metabolic changes required for optimal T cell activation, 
function, and differentiation. CTLA-4 opposes the effects of CD28 costimulation and can inhibit potent TCR-mediated signals. PD-1 inhibits weak but not strong 
TCR signals. The imbalanced activation of these signaling pathways alters the metabolic reprogramming of T cells and their differentiation fate (see text for details).
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T  cells, active Akt leads to increased Glut1 surface expression, 
improved coupling of HKII to the mitochondria, and increased 
rates of glycolysis, which correlates with proliferative capacity 
(6, 7, 53). Akt also promotes aerobic glycolysis by direct phos-
phorylation and activation of glycolytic enzymes, such as PFK2 
(59), by regulating Glut1 trafficking, and by inducing several 
transcription factors (60). Akt can activate mTORC1, a key driver 
of anabolic metabolism (61).
MAP kinases have a central role in metabolic regulation during 
T cell activation by affecting both glucose and glutamine uptake 
and metabolism (2, 62). One target of MAPK with a direct role 
on metabolic regulation is HIF1α. MAPK promotes the ability 
of HIF1α to activate transcription and expression of many gly-
colytic genes, while mediating suppression of genes involved in 
OXPHOS (63). HIF1α levels are also upregulated by PI(3,4,5)P3 
signaling through mTOR (61) providing a mechanistic explana-
tion for the requirement of simultaneous activation of PI3K 
and MAPK pathways for optimal effector T cell expansion (56). 
The critical role of HIF1α in T cell differentiation and function 
is underlined by the observation that T cells with constitutively 
elevated HIF1α display sustained increase of aerobic glycolysis 
and constitutively maintain effector function (64).
After TCR and costimulatory receptor engagement, T  cell 
activation is maintained by sustained signaling from IL-2 and 
other cytokines acting on common gamma chain (γc) cytokine 
receptor complexes (65). This effect of IL-2 leads to glycolysis and 
anabolic metabolism by activating transcriptional upregulation 
and trafficking of Glut1. This is mediated by Jak-STAT5 signaling 
(66) and also by activation of PI(3,4,5)P3/Akt (57).
T  cell receptor signaling pathways also lead to the genera-
tion of second messengers, diacylglycerol (DAG), and calcium. 
Calcium flux from intracellular stores stimulates the calcium-
activated mitochondrial dehydrogenases that drive the TCA cycle 
(67). In addition, calcium flux downstream of the TCR causes 
a short-term phosphorylation of AMPK mediated by CAMKK 
(68). AMPK acts as an important metabolic checkpoint to control 
cellular anabolic pathways and to induce energy-conserving 
mechanisms under conditions of nutrient shortage or cellular 
stress. AMPK activation early during the initiation of T  cell 
stimulation may facilitate transient increase of OXPHOS before 
the cells switch their metabolism toward glycolysis thereby sup-
porting the energy demands at this early T cell activation stage. 
Mechanistically, AMPK activation is induced by the upstream 
kinase LKB1 when the cellular levels of ATP are diminished 
and the levels of AMP and ADP are increased in response to 
physiological stress (69). During T  cell activation, in addition 
to regulation of energy, AMPK also provides metabolic fitness to 
the differentiating TEFF and TM cells (70). After activation, AMPK 
phosphorylates several substrates involved in the metabolism of 
glucose, lipid, and proteins, in autophagy, cell cycling, and cell 
growth (71). Activation of the TSC1/TSC2 complex by AMPK 
can negatively regulate the mTOR pathway (72, 73) not only by 
inhibiting mTOR activation via Rheb (74), a member of the Ras 
family of GTPases, but also by mediating phosphorylation of the 
mTORC1 partner Raptor (75).
COiNHiBiTORY ReCePTORS TARgeT 
SigNALiNg eveNTS THAT DRive T CeLL 
MeTABOLiC RePROgRAMMiNg
The key signaling pathways that are activated by antigen encoun-
ter are targets of costimulatory and coinhibitory receptors 
(Figure  3B). Costimulatory receptors amplify TCR-mediated 
signaling and impact T  cell metabolic reprogramming. For 
example, CD28-mediated costimulation mediates transcriptional 
upregulation of the glucose receptor Glut 1 (6) and the glutamine 
receptors Snat1 and Snat2 (62) after TCR ligation. Costimulation 
also amplifies MAPK and PI3K/Akt activation, and the simulta-
neous engagement of these signaling pathways is mandatory for 
cell cycle progression and cytokine production (56). Conversely, 
coinhibitory receptors oppose the signaling and functional effects 
induced by TCR and costimulatory pathways, thereby limiting 
T cell expansion and cytokine production and altering the abil-
ity of T cells to differentiate into TEFF and TM cells. Importantly, 
coinhibitory receptors do not induce global signal inhibition but 
rather selective targeting of signaling, resulting in imbalanced 
activation of pathways that are normally engaged by TCR-plus-
costimulation. As a consequence, the implications of coinhibitory 
pathways on the metabolic and functional programs of T  cells 
might significantly vary, dependent on the signaling targets of 
these inhibitory receptors.
Cytotoxic T Lymphocyte Antigen-4
The coinhibitory receptor CTLA-4 is a central negative regulator 
of T  cell activation. CTLA-4 is a homolog of CD28 and binds 
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to the same ligands, CD80 (B7-1) and CD86 (B7-2), but with 
higher affinity (76). CTLA-4 is induced in CD4+ and CD8+ 
T  cells after activation (77) but is constitutively expressed on 
TREG cells, because it is a direct transcriptional target of Foxp3 
(22). Crosslinking of the CTLA-4 simultaneously with TCR and 
CD28 inhibits cell cycle progression (78) and suppresses IL-2 
production leading to proliferative arrest (79, 80). Engagement of 
CTLA-4 can induce an anergic phenotype similar to that observed 
in response to TCR stimulation alone (78) establishing the notion 
that CTLA-4 might function to counteract CD28-mediated 
costimulation. Notably, the inhibitory functions of CTLA-4 on 
CD4+ T cells appear to be more important for the prevention of 
autoimmunity as CTLA-4-deficient CD8+ T cells are incapable of 
inducing autoimmune pathology in the absence of CD4+ T cells 
(81, 82). This may be due to the fact that CTLA-4 expression in 
CD4+ TREG is indispensable for the maintenance of TREG suppres-
sive function (22). However, direct CTLA-4-mediated inhibition 
of CD8+ T  cells may be particularly important in the effector/
memory CD8+ T  cells in which CTLA-4 controls secondary 
responses (83, 84).
CTLA-4 controls T  cell activation by selectively reversing 
CD28-mediated costimulation (79, 85). Because CTLA-4 is the 
high-affinity ligand for CD80 and CD86, CTLA-4 might inhibit 
activation by competing with CD28 for interaction with CD80 
and CD86. It can also downregulate the expression of CD80 and 
CD86 expression on APCs (22) or remove these costimulatory 
ligands from APCs through transendocytosis and, as a conse-
quence, reduce CD28 engagement (86). After binding to CD80/
CD86, CTLA-4 may also alter the properties of dendritic cells by 
inducing the tryptophan-degrading enzyme IDO, a known T cell 
inhibitor (87).
CTLA-4 also inhibits T cell activation through cell-intrinsic 
signaling mechanisms (88). The cytoplasmic tail of CTLA-4 
interacts with several molecules that are key components in 
TCR and CD28-mediated signaling pathways (Figure 3B). TCR/
CD28-mediated stimulation induces activation of several kinases, 
including Lck, Fyn, Lyn, Rlk, and Jak2, which are capable of phos-
phorylating Y165 and Y182 of the CTLA-4 cytoplasmic domain 
(89–92). Phosphorylation at Y165 creates a docking site for the 
protein tyrosine phosphatase SHP-2, which subsequently inhibits 
proximal TCR signaling via dephosphorylation of the TCRζ chain, 
LAT, and the Ras regulator p52SHC (93, 94). CTLA-4 interferes 
with the formation of lipid rafts, TCR:ZAP70 microclusters, and 
the central supramolecular activation complex, each of which 
plays important roles in T cell activation (89, 95, 96). CTLA-4 
has also been identified to interact with the serine/threonine 
phosphatase PP2A, leading to inhibition of Akt (97, 98).
The effects of CTLA-4 on depleting CD80 and CD86 costimu-
latory ligands and inhibiting TCR signaling pathways have major 
implications on regulation of metabolic reprogramming by cell-
intrinsic mechanisms. By dampening CD28-mediated signaling, 
which has a dominant role in regulating Glut1 expression and 
HKII activation (5, 6), CTLA-4 directly targets a key regulator of 
glucose transport, affecting intracellular glucose availability and 
glycolysis. Furthermore, by decreasing calcium release, which is 
involved in the activation of the TCA cycle (67), CTLA-4 can 
suppress not only glucose uptake and metabolism but also oxida-
tion of other metabolites in the TCA cycle. Furthermore, CTLA-4 
inhibits production of IL-2 (79, 80), by impairing the activation of 
and nuclear accumulation of AP-1, NFAT, and NF-κB (99, 100). 
Because IL-2 serves as an autocrine mechanism that activates and 
amplifies T  cell metabolic reprogramming toward a glycolytic 
phenotype (57), inhibition of IL-2 is an additional mechanism 
by which this coinhibitory receptor shuts off the activation of 
metabolism-related expansion and differentiation of T  cells 
downstream of the TCR and CD28.
A unique feature of CTLA-4 biology is related to its intracellular 
localization and trafficking. Specifically, the majority of CTLA-4 
resides within intracellular vesicles of the trans-Golgi network 
and endosomal compartments (101, 102). In resting T  cells, a 
small amount of CTLA-4 protein cycles continuously from the 
Golgi apparatus to the cell surface, followed by rapid endocytosis 
and lysosomal degradation (103). This intracellular trafficking is 
mediated by the interaction of the cytoplasmic tail of CTLA-4 
with the clathrin-associated adaptors AP-1 and AP-2/AP50 
(104, 105). During TCR ligation, CTLA-4 protein expression is 
increased, and CTLA-4-containing intracellular vesicles relocal-
ize to the immune synapse (102). The TCR-proximal kinases Lck 
and ZAP70 phosphorylate the cytoplasmic tail of CTLA-4 at 
Y165. This event leads to disruption of the CTLA-4:AP-2 associa-
tion and retention of CTLA-4 at the cell surface in the immune 
synapse (106). The more potent the TCR-mediated stimulation, 
the more CTLA-4 accumulates at the immune synapse. By this 
mechanism, CTLA-4 provides a dynamic inhibitory signal, which 
is fine-tuned by the intensity of the TCR signal (107). The con-
tinuous surface recycling and endocytosis of CTLA-4 in T cells 
and its rapid stabilization on the cell surface after T cell activation 
might be responsible for the potent inhibitory effect of CTLA-4, 
which is mediated early upon initiation of T cell activation for 
maintenance of an immune quiescent phenotype. Consistent with 
the biochemical evidence that CTLA-4 might rapidly inhibit TCR 
and CD28-mediated signaling, gene expression studies indicate 
that the net outcome of CTLA-4 ligation is the suppression of 
activation transcripts downstream of the TCR without specific 
targeting on metabolism-related genes (108).
Programmed Death-1
PD-1 is a transmembrane coinhibitory receptor that controls 
T cell activation, exhaustion, tolerance, and resolution of inflam-
mation. PD-1 appears within 24 h of T cell activation, declines 
with the clearance of antigen, and reappears in TM  cells (109, 
110). NFATc1, IRF9, and Notch promote PD-1 transcription 
(111–113), providing evidence that PD-1 expression requires 
not only TCR-proximal signaling but also generation of second 
messengers. When T cells are exposed to antigen for prolonged 
periods of time (as with chronic infection or cancer), the level 
of PD-1 expression remains high, and T  cells undergo various 
changes in transcription factor expression, which alter their 
differentiation program and guide the development of a distinct 
state termed “exhaustion.” It should be noted that this functional 
state is not mediated exclusively by PD-1. Under these condi-
tions, exhausted T (TEX) cells express multiple other coinhibitory 
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receptors in addition to PD-1, making them susceptible to inhibi-
tion by multiple checkpoint pathways. Depending on the number 
of coinhibitory receptors expressed, TEX cells display a different 
level of functional incompetence (114, 115). PD-1 can also be 
expressed on TREG and T follicular regulatory cells (21, 116), as 
well as on natural killer (NK), NKT, B cells, macrophages, and 
some DC subsets during immune activation and chronic inflam-
mation (20, 110, 117).
PD-1 has two known ligands, programmed death-ligand 1 
(PD-L1; also known as CD274 and B7-H1) and programmed 
death-ligand 2 (also known as CD273 and B7-DC) (20, 118). 
PD-1 ligands are expressed on APCs and other hematopoietic 
cells but also on non-hematopoietic cell types and are induced 
or upregulated by proinflammatory cytokines such as type I and 
type II interferons, TNF-α, VEGF, and GM-CSF. The induction 
of PD-1 ligands by proinflammatory signals might serve as a 
negative feedback mechanism that downregulates effector T cell 
activity, thereby protecting tissues from excessive immune dam-
age. These mechanisms are exploited by several pathogens and 
tumors to avoid attack from the immune system (13, 23).
Binding of PD-1 ligands to PD-1 results in tyrosine phos-
phorylation of the PD-1 cytoplasmic domain and recruitment 
of the tyrosine phosphatase SHP-2 (119). These events correlate 
with attenuated signals downstream of the TCR, decreased 
T cell activation and impaired cytokine production (Figure 3B). 
Signaling through PD-1 inhibits PI3K activity (120, 121). The 
main negative regulator of the PI3K/Akt pathway is PTEN, which 
is a lipid phosphatase, dephosphorylating PI(3,4,5)P3 at the 3′ 
position to generate PI(4,5)P2 (122). By limiting the amount of 
PI(3,4,5)P3, PTEN opposes the activation of PI3K and therefore 
diminishes the pro-survival and proliferative signals mediated by 
PI3K/Akt (123). PD-1 activates PTEN phosphatase by inhibit-
ing its inactivating phosphorylation by CK2 (120), leading to 
diminished activation of Akt and decreased expression of critical 
transcription factors such as Tbx21 (T-bet), Eomes, and Gata3, 
which are involved in the function of effector cells. PD-1 ligation 
also inhibits Ras-MEK-ERK pathway signaling, possibly via SHP-
2-regulated dephosphorylation of PLCγ1 (124), which is required 
for Ras activation via calcium- and DAG-dependent activation of 
Ras-GRP1 (125). Thus, PD-1 targets many pathways that have a 
decisive role in metabolic reprogramming of T cells after antigen 
encounter.
As a consequence of these signaling events, after PD-1 
engagement, T  cells have significantly diminished capacity to 
activate glycolysis, have reduced respiration, a function that 
depends on mitochondria, and also have altered lipid metabo-
lism characterized by suppression of fatty acid synthesis and 
elevated FAO (126). Subsequently, T cells are unable to become 
effectors, a fate that requires engagement in glycolysis as well as 
potent mitochondrial function (51). Instead, PD-1 can promote 
the differentiation of TREG cells, which suppress TEFF functions 
(21). Because TREG differentiation depends on FAO and lack of 
glycolysis (47), it is possible that the effects of PD-1 on T cell 
metabolic reprogramming are responsible for the switch of the 
T  cell functional fate from TEFF to TREG differentiation. Such 
effects on immunometabolic programs may also have a causative 
role in the control of peripheral tolerance by PD-1 because PD-1 
signaling inhibits aerobic glycolysis, which is required for Th1 
and Th17 cell differentiation (51) and metabolically reprograms 
T  cells from aerobic glycolysis to FAO (126), which promotes 
the generation of TREG cells. Notably, the downregulation of 
Akt, mTOR, and S6K, which is induced by PD-1, has been 
previously identified as a requirement for the development of 
peripheral TREG cells (127). Moreover, PD-1 ligation in TEFF cells 
might reprogram TEFF cells from aerobic glycolysis and FAS to 
catabolic lipid metabolism and FAO. By selectively inducing 
metabolic reprogramming of TEFF cells from glycolysis to FAO, 
PD-1 can guide differentiation of TEFF cells to TREG to terminate 
the ongoing immune responses and to TM cells to maintain the 
T  cell repertoire as differentiation of both these cell programs 
depends on FAO (37, 47).
By targeting metabolic reprogramming, the PD-1:PD-L1 
pathway might also alter metabolism in the tumor microenviron-
ment. Changes in metabolism of T cells and tumor cells will have 
a central role in antitumor immune responses. Highly glycolytic 
tumor cells reduce glucose levels in the tumor microenviron-
ment, thereby reducing the ability of tumor-infiltrating lympho-
cytes (TILs) to mount effector antitumor immune responses. 
Moreover, ligation of PD-1 by PD-L1 expressed by tumor or APC 
of the tumor microenvironment shuts off glycolysis and mito-
chondrial function of TIL leading to impaired effector function. 
Simultaneously, by this mechanism, TREG cells are preferentially 
generated in the tumor microenvironment leading to progres-
sive immunosuppression through additional TEFF cell-extrinsic 
mechanisms.
Other Coinhibitory Pathways
In addition to CTLA-4 and PD-1, multiple other coinhibitory 
molecules exist including LAG-3, TIM-3, TIGIT, CD160, BTLA, 
B7-H3, B7-H4, VISTA, CD244, HHLA2, and BTNL2 (Figure 1). 
Several of these coinhibitory receptors are expressed on dysfunc-
tional T cells similarly to PD-1. T cell subsets coexpressing mul-
tiple coinhibitory receptors are more dysfunctional than those 
expressing each coinhibitory receptor alone. The coexpression of 
coinhibitory receptors has important clinical relevance because 
combined blockade with PD-1 significantly enhances therapeutic 
benefit.
Lymphocyte Activation gene-3
LAG-3 is a CD4 homolog that binds MHC class II molecules 
with higher affinity than CD4 (128). Among T cells, LAG-3 is 
expressed on activated CD4+ and CD8+ T  cells, as well as in 
thymic and peripherally induced TREG (129). It is also expressed 
in NK cells, NKT cells, B cells, and plasmacytoid dendritic cells. 
LAG-3 negatively regulates T cell proliferation and homeosta-
sis (130, 131). The KIEELE motif of the cytoplasmic domain 
of LAG-3 is involved in its inhibitory function (132), but the 
downstream signaling pathways mediating the inhibitory effect 
have not been identified. LAG-3 regulates peripheral T  cell 
tolerance by controlling self-reactive effector cells and TREG 
(133–135). Mice lacking both LAG-3 and PD-1 rapidly develop 
lethal, systemic autoimmunity (136), providing evidence that 
these two pathways control T  cell tolerance in a synergistic 
manner.
9Patsoukis et al. Coinhibitory Receptors in T Cell Metabolism
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 330
T cells in chronic viral infections and tumors often coexpress 
PD-1 and LAG-3. Furthermore, consistent with the synergistic 
effect in T  cell autoimmunity induced by combined deficiency 
of PD-1 and LAG-3, combined blockade of PD-1 and LAG-3 in 
the lymphocytic choriomeningitis virus (LCMV) chronic infec-
tion model or in tumor models has a greater therapeutic benefit 
than blockade of each coinhibitory receptor alone. In this regard, 
LAG-3 and PD-1 blockade together can induce almost complete 
tumor regression in mice with established MC38 or SA1N tumors, 
in contrast to only ~15% efficacy when only one of the two 
receptors is blocked (137). Similarly, in TILs from patients with 
ovarian cancer, simultaneous LAG-3 and PD-1 blockade restores 
responsiveness of NY-ESO-1-specific LAG3+/PD-1+ CD8+ T cells 
to a greater extent than blockade of each coinhibitory receptor 
alone. Thus, although it remains unclear how LAG-3 affects sign-
aling pathways regulated by TCR, the functional synergy between 
PD-1 and LAG-3 suggests that LAG-3 might target pathways 
not affected by PD-1 and, as a consequence, combined signals 
mediated by these coinhibitory receptors result in more profound 
impairment of TEFF cell function.
Recent studies have shown that LAG-3 is cleaved within the 
short connecting peptide between the membrane proximal D4 
domain and the transmembrane domain, which is mediated 
by ADAM family metalloproteases, resulting in the release of a 
soluble form of LAG-3 (sLAG-3) in vitro and in vivo (138). LAG-3 
expression and function might be linked to oxidative signals 
generated by metabolic reprogramming of activated T  cells. 
Treatment with an antioxidant superoxide dismutase (SOD)-
mimetic compound prevented type I diabetes in mouse models 
by inhibiting metalloprotease activity resulting in maintenance 
of LAG-3 surface expression at levels adequate to attenuate TCR-
mediated Th1 cell activation and effector function (139). It has 
also been determined that LAG-3−/− splenocytes exhibit enhanced 
SRC, which correlates with increased mitochondrial mass and 
expression of the mitochondrial biogenesis transcription factor 
TFAM and mitochondrial complexes I–IV (140). Moreover, 
after suboptimal stimulation with Con-A, LAG-3−/− splenocytes 
demonstrated greater upregulation of glycolysis-associated genes 
together with elevated expression of Myc and mTOR signaling 
(140), which are crucial for driving aerobic glycolysis. Thus, 
LAG-3 might regulate T  cell exhaustion in conjunction with 
PD-1 because LAG-3 and PD-1 signals converge into regulating 
glycolytic metabolism and mitochondrial function both of which 
are involved in the differentiation of TEFF cells.
T Cell-immunoglobulin–Mucin Domain 3
TIM-3 was initially identified at the cell surface of IFN-γ-
producing CD4+ Th1 and CD8+ cytotoxic T  cells (141). In 
addition, TIM-3 is expressed in TREG cells and innate immune 
cells such as DCs, NK  cells, and monocytes. The discovery of 
TIM-3 led to the identification of the TIM family of genes (142), 
and examination of TIM-3 function with TIM-3-deficient mice, 
blocking antibodies, and TIM-3-Ig fusion protein suggest that 
TIM-3 family members function as negative regulators of T cell 
responses (141, 143, 144). Several ligands for TIM-3 have been 
identified, including C-type lectin galectin-9, phosphatidylserine 
(PtdSer), HMGB1, and CEACAM-1 (145–147). The mechanism 
of TIM-3-mediated inhibitory function differs from that of other 
coinhibitory receptors because TIM-3 has the unique ability to 
induce PtdSer-mediated recognition and phagocytosis. It has 
been postulated that blocking TIM-3 alters the immune response 
induced by recognition of dying tumor cells (148).
TIM-3 does not have a classical signaling motif in its cytoplas-
mic tail but contains five conserved tyrosine residues. Y256 and 
Y263 can be phosphorylated by Src kinases (149) or ITK (150) 
and are involved in the binding of Bat3 (HLA-B associated tran-
script 3), p85 PI3K, Fyn, and/or Lck (149, 151). When TIM-3 is 
not bound to its ligands, Bat3 is bound to TIM-3 and blocks SH2 
domain-binding sites in TIM-3 tail and recruits the catalytically 
active form of Lck that preserves and promotes T cell signaling. 
In contrast, in the absence of Bat3, interaction of TIM-3 tail with 
the catalytically inactive form of Lck pY505 increases (151). 
Galectin-9 and CEACAM-1 binding to TIM-3 leads to Y256 and 
Y263 phosphorylation and release of Bat3 from the TIM-3 tail, 
thus promoting TIM-3-mediated T  cell inhibition by allowing 
binding of Src kinases, preferentially Fyn (147, 151). Interestingly, 
Fyn and Bat3 compete for the same region on the TIM-3 tail. 
Although it is clear from these studies that the cytoplasmic tail 
of TIM-3 has the potential to interact with multiple components 
of the TCR complex, the precise mechanisms via which TIM-3 
alters T cell signaling remains to be elucidated.
It has been determined that TIM-3+ T cells from HIV-infected 
patients display defective stimulation-induced phosphorylation 
of Stat5, ERK1/2, and p38 but have higher basal phosphoryla-
tion of these pathways (152). These CD8+TIM-3+ dysfunctional 
T cells lacked PD-1 expression suggesting that TIM-3 might be 
an alternative exhaustion-related inhibitory receptor and bio-
marker. However, when coexpressed with PD-1, TIM-3 marks 
the most dysfunctional/exhausted population in patients with 
chronic viral infections (153–155). Similarly, coexpression of 
TIM-3 with PD-1 also marks the most dysfunctional TEX CD8+ 
cells in cancer (156).
Because TIM-3 targets key metabolism-related signaling 
pathways, such as PI3K/Akt/mTOR (157), and is highly expressed 
on dysfunctional or TEX cells in chronic infections (152–155, 158) 
and TILs in various types of cancers (159–161), it is possible that 
TIM-3-mediated effects alter metabolism of T effector cells in a 
manner similar to PD-1. Alternatively, the additive and synergis-
tic effect of combined PD-1 and TIM-3 blockade in the functional 
re-invigoration of TEX cells might be explained by a selective role 
of TIM-3 on metabolic programs that are not affected by PD-1.
T Cell immunoglobulin and iTiM Domain
The coinhibitory receptor TIGIT (also called Vsig9, Vstm3, or 
WUCAM) is an immunoglobulin superfamily member (162, 
163). It belongs to a group of stimulatory and inhibitory recep-
tors and ligands that bind to these receptors (164). TIGIT and 
the costimulatory receptor CD226 (DNAM-1) share the ligands 
CD155 and CD112 with TIGIT as their high-affinity receptor. 
TIGIT also binds to CD113 whereas CD155 also binds to the 
inhibitory receptor CD96 (Figure  1). CD155 and CD112 are 
expressed on APCs and on several cancers, whereas CD155 is also 
expressed on several non-hematopoietic cells. TIGIT is induced 
after T  cell activation and is expressed in TEFF, TM, TREG, and 
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NK cells. TIGIT can exert immunosuppressive effects by various 
mechanisms. By engaging CD155 on dendritic cells, TIGIT can 
inhibit IL-12 production by dendritic cells, thereby preventing 
Th1 differentiation and functional responses (165). TIGIT also 
can mediate cell-intrinsic inhibitory effects on T  cells and can 
inhibit priming of CD4+ and CD8+ T  cells (166). Thus, TIGIT 
can promote T cell tolerance by controlling both the activation of 
self-reactive T cells and the function of TREG (167).
TIGIT cytoplasmic tail has an ITIM motif and an immuno-
globulin tail tyrosine (ITT)-like motif (164). The ITT-like motif 
plays a critical role in inhibitory signaling as binding of CD155 
to TIGIT induces phosphorylation of the ITT motif and recruit-
ment of SHIP1, which correlates with inhibition of NF-κB path-
way activation. TIGIT is expressed on CD8+ TILs either alone 
or together with PD-1 in various human cancer types (168). In 
mouse cancer models, in contrast to minimal effects of blockade 
of TIGIT or PD-L1 alone, combined blockade of TIGIT and 
PD-L1 can induce substantial tumor regression and improved 
survival by enhancing the function of CD8+ TILs (169). Similarly, 
synergistic effects of combined PD-L1 and TIGIT blockade have 
been observed in the LCMV chronic viral infection model to 
reverse T cell exhaustion and enhance viral control (169). These 
findings suggest functional synergies between PD-1 and TIGIT 
and support exploration of combined TIGIT and PD-1 blockade 
for re-invigoration of immune responses.
CD160/BTLA/LigHT/HveM
CD160 was discovered in an effort to identify NK  cell-specific 
receptors (170) and contains a single IgV-like domain and a 
glycosyl-phosphatidylinositol (GPI)-anchor (171). CD160 inter-
acts with classical and non-classical MHC class I molecules with 
weak affinity (172). CD160 is expressed in secondary lymphoid 
organs, intestinal lymphocytes, and peripheral CD8 and NK cells 
(171). Although originally thought to be involved in the cytolytic 
activity of CD8+ T cells, CD160 was subsequently identified as one 
of the coinhibitory receptors expressed in CD8+ TEX cells. In fact, 
together with PD-1, CTLA-4, LAG-3, and CD224, CD160 is one 
of the coinhibitory receptors that are progressively upregulated 
as the CD8+ cell effector function declines during the differen-
tiation to TEX cells (115). Increasing numbers of CD160+ T cells 
are detected during HIV infection and are higher in patients 
who have optimal control of HIV (173) providing, once more, 
evidence about the active role of TEX cells in the containment of 
chronic viral infections.
B and T  lymphocyte attenuator was identified as another 
coinhibitory receptor of the Ig superfamily, related to CTLA-4 
and PD-1 (174, 175). The highest BTLA level is detected in B cells 
but is also expressed on T cells, DCs, and macrophages (174, 175). 
In contrast to other coinhibitory receptors, BTLA is moderately 
expressed on naïve T cells, transiently upregulated upon antigenic 
stimulation, and downregulated in activated T cells (176). BTLA 
is highly expressed in anergic T  cells generated in  vivo (177). 
Although BTLA has a different expression pattern from other 
coinhibitory receptors, extensive studies have showed that BTLA 
has a direct inhibitory effect on T cell proliferation and cytokine 
production. In vitro stimulation of BTLA-deficient T  cells 
resulted in enhanced proliferation in response to anti-CD3 (174, 
175). Conversely, retroviral overexpression of BTLA in DO11.10 
cells suppressed anti-CD3-mediated production of IL-2 (175). 
BTLA-deficient mice develop elevated autoantibodies and organ 
infiltration by activated CD4+ T cells indicating that BTLA has 
an active role in T  cell tolerance (178). Consistent with a role 
of BTLA in maintaining peripheral tolerance, BTLA-deficient 
mice have increased susceptibility to experimental autoimmune 
encephalitis, whereas induction of oral tolerance is also compro-
mised (175, 179).
A common ligand for CD160 and BTLA is the HVEM, which 
is a member of the tumor necrosis factor receptor superfamily, 
also known as TNFR superfamily 14 (180, 181). As mentioned 
above, the interaction of BTLA, which belongs to the Ig super-
family, with HVEM, which is a member of the TNF receptor 
superfamily, is a rare example of cross talk between members of 
different families of coinhibitory receptors and ligands. HVEM 
also interacts with another TNFR-associated factor-associated 
receptor, TNF receptor-like molecule 2, or LIGHT receptor 
(182). HVEM was initially discovered as a molecule that interacts 
with viral glycoprotein D to facilitate entry of herpes simplex 
virus (183). It is expressed in hematopoietic cells and nearly all 
parenchymal tissues with highest expression in lung, liver, and 
kidney, and lower expression in brain, pancreas, heart, placenta, 
and skeletal muscle (183). HVEM is expressed in high levels 
in naïve T cells, is transiently decreased after activation and is 
upregulated at the late activation stage (180, 184). Interaction 
of HVEM with LIGHT induces T  cell proliferation whereas 
blockade of LIGHT: HVEM interaction inhibits responses of 
activated T cells (182). Thus, the CD160/BTLA/LIGHT/HVEM 
pathway mediates coinhibitory signals through the engagement 
of CD160 and BTLA with HVEM but promotes T cell activa-
tion by engagement of LIGHT. The distinct functions of HVEM 
ligands are mediated via distinct binding sites on HVEM. 
Specifically, HVEM has three cysteine-rich domains (CRDs) and 
a fourth CRD that is less typical and has only two of the three 
disulfide bonds (18, 183). The CRD1 is required for coinhibitory 
binding of HVEM with CD160 and BTLA but has no role in 
the costimulatory binding with LIGHT (180, 181). Deletion of 
CRD1 can convert the function of HVEM from a coinhibitory 
receptor, which seems to be its net effect, into a solely costimula-
tory receptor (181).
Little is known about the signaling pathways engaged by 
HVEM downstream of BTLA and CD160. BTLA contains 
two conserved ITIMs in its cytoplasmic tail (129), which are 
phosphorylated on Y274 and Y299 upon BTLA ligation and 
result in recruitment of SHP-1 and SHP-2 (18, 174, 175, 185). 
CD160, a GPI-anchor protein, is localized at the lipid rafts. By 
this localization, CD160 can regulate activation of key compo-
nents of the TCR-proximal signaling machinery when engaged 
in cytolytic function (186). However, the mechanism via which 
CD160 inhibits T cell responses remains elusive. Currently, there 
is no information of how CD160 and BTLA might affect T cell 
immunometabolic programs. The involvement of BTLA in the 
maintenance of self-tolerance, the role of CD160 as coinhibitory 
receptor on TEX cells, and their reciprocal expression in naïve 
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versus activated T cells strongly suggest that together CD160 and 
BTLA must play an important role in the fine tuning of metabolic 
programs that determine T cell fate and function upon encounter 
of self-antigens, pathogens, or tumor antigens. Furthermore, the 
ability of HVEM to switch its properties from being a mediator 
of inhibitory signals via interaction with CD160 and BTLA to 
being a T cell costimulator via interaction with LIGHT indicates 
that the CD160/BTLA/LIGHT/HVEM pathway might regulate 
immunometabolic plasticity that rapidly switches T cell differen-
tiation programs and guides distinct functional outcomes.
T CeLL-iNTRiNSiC iMMUNOMeTABOLiC 
RegULATiONS MeDiATeD BY 
CHeCKPOiNT iNHiBiTORS
The extensive studies regarding the expression and function 
of coinhibitory receptors provide currently emerging evidence 
that these receptors have synergistic roles in suppressing T cell 
function and provide evidence for their non-redundant roles in 
inhibiting the responses of activated T cells. Although the evo-
lutional purpose for the coexpression of multiple coinhibitory 
receptors is not clearly understood, several observations provide 
challenging hypotheses. It is possible that coinhibitory receptors 
are expressed in distinct combinations on T cell subsets depend-
ing on the type of activation signals that such T  cells receive, 
which might depend on the engagement of distinct costimula-
tory receptors or on the activation of autocrine and paracrine 
cytokine loops. For example, expression and recruitment of 
CTLA-4 to the immunological synapse depend on the strength 
of the TCR signal (107). It is also possible that ligands for the 
different coinhibitory receptors are differentially expressed in 
various tissues or tissue resident APC and, as a consequence, 
distinct coinhibitory receptors control T  cell responses in dis-
tinct microenvironments. For example, parenchymal tissues and 
organs express ligands for PD-1 but not for CTLA-4 (20). As 
nutrients and metabolites provide important environmental cues 
with decisive role in T  cell activation (187), it is also possible 
that distinct metabolic programs of various microenvironments 
selectively promote the expression and function of different 
coinhibitory receptors. For example, protection from oxidative 
damage mediated by reactive oxygen species (ROS) by an SOD-
mimetic compound, resulted in elevated expression of LAG-3 in 
T cells and inhibition of TCR-mediated Th1 cell activation and 
effector function (139). Such metabolism-driven events might 
also differentially regulate the expression of coinhibitory recep-
tors in T cell subsets (53).
Currently, there is little known about the metabolic repercus-
sions of coinhibitory receptors on T  cells and the metabolic 
consequences by targeting these immune checkpoint pathways 
in pathogen-specific and tumor-specific T  cells. The immu-
nometabolic effects mediated by the most clinically relevant 
coinhibitory receptors, CTLA-4 and PD-1, are starting to be 
elucidated. Laboratory studies have provided evidence that 
inhibitory checkpoint pathways can alter the metabolic program 
of T cells (126, 188). PD-1 engagement makes T cells unable to 
engage in glycolysis, glutaminolysis, or amino acid metabolism 
but increases FAO (126). This effect is due to inhibition of trans-
port and utilization of glucose and glutamine. In contrast, PD-1 
promotes FAO of endogenous lipids by inhibiting the lipid oxida-
tion PI3K pathway, resulting in increased expression of carnitine 
palmitoyltransferase 1A (CPT1A), the rate-limiting enzyme of 
FAO, which plays an important role in the utilization of fatty acids 
as an energy source. In parallel, PD-1 abrogates the induction of 
fatty acid synthase and, as a consequence, decreases anabolic lipid 
metabolism and biosynthesis of lipids, which normally occurs 
during T cell activation.
Compared to T  cells activated without PD-1 ligation, acti-
vated T  cells receiving PD-1 signals have lower extracellular 
acidification rate (ECAR), an indicator of glycolysis, and lower 
oxygen consumption rate, an indicator of OXPHOS. These 
findings indicate that T  cells receiving PD-1 signals are rather 
metabolically quiescent and preferentially use OXPHOS over gly-
colysis as indicated by the higher OCR/ECAR ratio. As fat-based 
metabolism is associated with longevity (189), the augmentation 
of FAO may explain the longevity of T cells, which engage the 
PD-1 pathway, in patients with chronic infections and cancer and 
their ability to be reinvigorated by blockade of PD-1. The role of 
PD-1:PD-L1 pathway in restricting glucose metabolism in vivo 
was also reported in a study of graft-versus-host disease in mice, 
where recipients of allogenic bone marrow deficient in PD-L1 
had higher levels of Glut1 and lactate production (190).
Because of the increased FAO and the elevated OCR/ECAR 
ratio, it is possible that PD-1-mediated inhibitory effects in T cells 
might be related to a more oxidative environment. Although deple-
tion of the antioxidant glutathione (GSH) was observed in T cells 
stimulated with or without PD-1 ligation, consistent with the 
expected increase of ROS during TCR-mediated activation (191, 
192), PD-1 ligation resulted in more pronounced decrease in the 
levels of reduced GSH. However, under these conditions, T cells 
had higher levels of cysteine-GSH disulfide and ophthtalmate, a 
GSH-like product that is synthesized by the same enzymes (126). 
These changes might be suggestive of a more oxidative environ-
ment in T cells receiving TCR signals in conjunction with PD-1 
ligation. However, several other tentative mechanisms might 
be implicated in these observations. In alloreactive T cells after 
allogeneic bone marrow transplantation, PD-1 expression has 
been correlated with an oxidative environment, ROS production, 
and higher susceptibility of these cells to metabolic inhibition by 
F1F0-ATP synthase complex inhibitors (193). Thus, expression 
and function of PD-1 and possibly other coinhibitory receptors 
might be linked with the T cell oxidative state, which can serve as 
a fine-tuning system of cellular differentiation.
A key mediator of oxidative detoxification is the PPARγ 
coactivator-1a (PGC-1α) (194, 195). Induction of PGC-1α dur-
ing caloric restriction mediates selective cell adaptations that 
provide modifications permissive for cell survival and function 
under increased OXPHOS. Because PGC-1α is regulated by 
mTOR (196), which is downstream of PI3K/Akt pathway that 
is targeted by PD-1 (120, 121), it was hypothesized that by 
dysregulating PGC-1α expression and function, PD-1 might 
impair oxidative detoxification. Moreover, different subsets of 
TEX cells might have distinct metabolic and bioenergetics prop-
erties such as mitochondrial biogenesis, which might correlate 
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with glycolysis, SRC, CPT1A, and PGC-1α (126). Consistent 
with this hypothesis, studies in chronic LCMV infection, 
which leads to the generation of various subsets of TEX cells, 
showed that the development of intermediate PD-1 (PD-1int) 
TEX cells correlated with reduced glucose uptake and glycolysis, 
dysregulated mitochondrial bioenergetics, and suppressed 
PGC-1α expression. PGC-1α expression was enhanced in the 
absence of PD-1, and forced expression of PGC-1α partially 
reverted some of the metabolic derangements of PD-1Int—but 
not in PD-1Hi—TEX cells and improved effector function (197). 
Similarly to the observations of in  vitro stimulated human 
T cells (126), transcriptional analysis during TEX development 
in response to LCMV infection revealed enrichment of genes 
involved in OXPHOS, particularly CPT1A (197). While these 
results point to a strong connection between PD-1-mediated 
metabolic reprogramming and induction of T cell exhaustion, 
it should be pointed out that similar bioenergetics mechanisms 
of T cell exhaustion in vivo mediated by chronic infection and 
cancer can also occur in a PD-1-independent manner (198, 
199). Thus, other coinhibitory receptors might mediate similar 
immunometabolic effects, thereby resulting in differentiation of 
functionally impaired T cells.
As mentioned above, PD-1 together with several other coin-
hibitory receptors coregulate T  cell exhaustion during cancer 
and chronic infections. Pathogen-specific CD8+ T cells in mouse 
models and humans with chronic viral infections as well as 
TILs from mouse tumor models and patients with cancer can 
coexpress multiple repressors, including PD-1, LAG-3, TIM-3, 
TIGIT, and others. The pattern and number of coinhibitory 
receptors expressed on the same cell can dramatically influence 
the severity of exhaustion (114, 115). T cell exhaustion is an active 
process and can lead to measurable consequences on T cell func-
tion. Studies have shown that distinct subsets of TEX cells exist, 
which have different potentials for recovery after PD-1 blockade. 
Although TEX cells with PD-1int expression can be reinvigorated 
by PD-1 blockade, TEX cells with high PD-1 (PD-1high) expression 
cannot (115). These distinct subsets of TEX cells may also have 
different metabolic and bioenergetics properties depending on 
the nature of coinhibitory receptors expressed and engaged on 
their surface. Identification of the unique bioenergetics profiles 
of TEX subsets might provide new tools to identify the level of 
exhaustion mediated by the combined and synergistic effects 
of coinhibitory receptors. It might also provide novel targets to 
reverse exhaustion and might serve as meaningful biomarkers to 
assess response to checkpoint inhibitor therapies.
In contrast to the effects of PD-1 in T cell metabolic reprogram-
ming, CTLA-4 inhibits glycolysis without augmenting CPT1A 
and FAO, suggesting that CTLA-4 maintains immune quiescence 
by preserving the metabolic profile of non-stimulated cells (126). 
RNA-seq of TILs from progressor sarcoma tumors in mice that 
were either treated with control, anti-CTLA-4, anti-PD-1 block-
ing antibodies, or a combination of anti-CTLA-4 and anti-PD-1 
antibodies revealed differential gene enrichment. PD-1 blocking 
showed enrichment predominantly in metabolic genes, while 
CTLA-4 blocking showed enrichment in cell cycle and effector 
memory genes. The combination of PD-1 and CTLA-4 antibody 
treatment revealed synergism of metabolic and T  cell effector 
genes that correlated with the strongest enhancement of effector 
molecules (108). The distinct properties of CTLA-4 and PD-1 
in affecting T  cell metabolic reprogramming might be related 
to their differential ability to oppose signals mediated by the 
TCR. CTLA-4 mediates a potent inhibition of T cell activation, 
and CTLA-4 recruitment at the immune synapse is regulated 
by the strength of TCR signal (107). In contrast, PD-1 inhibits 
weak but not strong TCR signals (200). As a consequence, TCR-
mediated biochemical events might be impaired but not fully 
abrogated (124, 201). Notably, the strength of PD-1 signaling 
also differentially affects TEFF cell function (201). This rheostat 
effect of PD-1 on TCR signaling that likely depends on the level 
of PD-1 expression might mediate fine tuning of metabolic 
reprogramming leading to distinct T  cell functional fates. The 
different immunometabolic implications of CTLA-4 and PD-1 
in T  cells, serve as a paradigm that provides evidence for the 
purpose of multiple coinhibitory receptors, which likely have 
unique roles in regulating immunometabolic programs and 
functional commitment of T  cells. Mechanistic understanding 
of the immunometabolic effects of coinhibitory receptors will 
shed light not only to the state of T cell functional impairment 
and exhaustion in chronic infections and cancer but also to the 
metabolic regulation of T cell tolerance.
COiNHiBiTORY ReCePTORS AFFeCT 
iMMUNOMeTABOLiC T CeLL 
ReSPONSeS BY RegULATiNg CROSS 
TALK wiTH iNNATe iMMUNe CeLLS AND 
CANCeR
It has become increasingly understood that coordinated meta-
bolic switches in T cells and innate immune cells modulate cel-
lular activities and contribute to the progression of cancer and 
chronic infections. Metabolic communication among T  cells, 
innate immune cells, and cancer might contribute to immuno-
metabolic regulations and fine tuning of the activation and anti-
tumor responses of T cells and myeloid cells (202) (Figure 4). 
In this regard, immunometabolic regulations mediated by 
coinhibitory receptors can impact T cell immune responses due 
to direct T cell-intrinsic signaling and by altering the metabolic 
properties and the differentiation program of innate immune 
cells (203). Not only the coinhibitory receptor ligands but also 
the coinhibitory receptors themselves are also present in various 
types of innate immune cells in addition to T cells. Intriguingly, 
it was recently reported that the PD-1: PD-L1 axis is implicated 
in immune metabolic dysfunctions of monocytes in chronic 
lymphocytic leukemia (203). In that system, triggering PD-1 
checkpoint on monocytes hampers glycolysis and phagocytosis. 
Conversely, disrupting PD-1: PD-L1 signaling reverses these 
immune metabolic dysfunctions. Taken together, these find-
ings imply a novel metabolic interplay between cancer cells 
and monocytes and that blocking PD-1: PD-L1 might restore 
metabolic together with antitumor activity of monocytes/
macrophages.
In a sarcoma tumor model, it was reported that expression 
of PD-L1 on cancer cells was associated with cell-intrinsic 
FigURe 4 | immunometabolic regulations mediated by coinhibitory receptors in innate immune cells and cancer can impact T cell immune 
responses. Metabolic signaling mediated by the programmed death-1 (PD-1):programmed death-ligand 1 (PD-L1) pathway in cancer or myeloid cells of the tumor 
microenvironment might subsequently alter T cell metabolic reprogramming and immune function due to nutrient competition and by generating metabolic products 
with detrimental effects on T cell immune function. PD-1 and PD-L1 might activate glycolysis in cancer cells, whereas PD-1 ligation might inhibit glycolysis of 
monocytes/macrophages in the context of cancer.
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signaling via the PI3K/Akt pathway and mTOR, leading 
to expression of glycolysis genes and enhanced glycolytic 
metabolism (204). Although it is unclear whether PD-L1 can 
trigger reverse signals to tumor cells by its short cytoplasmic 
tail that does not have obvious signaling motifs, PD-L1 func-
tions as an inhibitory receptor that protects cancer cells from 
immune-mediated cancer cell destruction and Fas-mediated 
killing (205). Because cancer cells have elevated activation of 
the PI3K/Akt pathway and are highly glycolytic, expression 
of PD-L1 might result in concomitant increase of PI3K/Akt 
activation and elevated rate of tumor-intrinsic glycolysis as a 
consequence of improved survival. It has also been observed 
that subpopulations of certain human and murine melanoma 
cell lines and subpopulations of malignant cells from patients 
with melanomas express PD-1 (206, 207). However, in contrast 
to T  cells, in which PD-1 ligation inhibits the activation of 
PI3K/Akt, MAPK, and mTOR pathways, ligation of PD-1 in 
melanoma cells was reported to activate these pathways and 
to promote expression of glycolytic enzymes, which correlate 
with tumor growth (206). To date, such finding of cancer 
cell-intrinsic growth-promoting effects of PD-1 have not been 
validated in tumor models and primary cancer cells. It is also 
unclear whether PD-L1 naturally expressed on tumor cells can 
trigger activation of glycolytic metabolism in cancer cells and 
whether such effect might be associated with tumor growth. 
However, together these findings (203, 204, 206) suggest that 
cell-intrinsic metabolic signaling mediated by the PD-1:PD-L1 
pathway in cancer or myeloid cells of the tumor microenviron-
ment might subsequently alter T cell immunometabolism and 
immune function due to nutrient competition and by gener-
ating metabolic products with detrimental effects on T  cell 
immune function (208).
CONCLUDiNg ReMARKS
Coinhibitory receptors have a major impact on the metabolic 
programs that drive the differentiation and functional fate of 
naïve T cells. These coinhibitory receptors have a major role in 
reprogramming the metabolic preferences of TEFF cells leading 
to metabolic and functional switches. Because coinhibitory 
receptors mediate distinct effects on the activation of signaling 
pathways, the role of coinhibitory receptors on altering T  cell 
immunometabolism is also anticipated to be distinct. Identifying 
and targeting the specific immunometabolic determinants relayed 
by different coinhibitory receptors might have significant clinical 
implications as selective receptor targeting might be employed in 
order to achieve specific desired modifications in the metabolic 
programs and functional fates of T cells.
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Metabolic determinants of different microenvironments pro-
vide important cues to drive differentiation and function of T cells 
by metabolism-based mechanisms. Expression and engagement 
of coinhibitory receptors after T cell activation can provide the 
necessary signals to terminate immune responses by altering the 
metabolic programs of antigen-specific TEFF cells. Such metabolic 
reprogramming might lead to conversion of TEFF to TREG and TM 
for termination of immune activation and maintenance of the 
T cell repertoire, respectively. Understanding and recapitulating 
the metabolic programs mediated by coinhibitory receptors will 
have implications for the induction of self-tolerance and the 
treatment of autoimmune diseases. Conversely, blocking and 
reversing metabolic programs mediated by coinhibitory receptors 
will promote TEFF differentiation and function and will improve 
immune-based therapies mediated by checkpoint inhibitors and 
by adoptive immunotherapy of ex vivo engineered T cells for the 
treatment of cancer and chronic infections. Exploiting the role 
of the coinhibitory receptors in T cells, innate immune cells and 
cancer will be a major challenge.
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